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ANG-(3–4) inhibits renal Na-ATPase in hypertensive rats through a mech-
anism that involves dissociation of ANG II receptors, heterodimers, and
PKA. Am J Physiol Renal Physiol 306: F855–F863, 2014. First published
February 12, 2014; doi:10.1152/ajprenal.00488.2013.—The physiological
roles of ANG-(3–4) (Val-Tyr), a potent ANG II-derived peptide,
remain largely unknown. The present study 1)investigates whether
ANG-(3–4) modulates ouabain-resistant Na-ATPase resident in
proximal tubule cells and 2) verifies whether its possible action on
pumping activity, considered the fine tuner of Na reabsorption in this
nephron segment, depends on blood pressure. ANG-(3–4) inhibited
Na-ATPase activity in membranes of spontaneously hypertensive
rats (SHR) at nanomolar concentrations, with no effect in Wistar-
Kyoto (WKY) rats or on Na-K-ATPase. PD123319 (107 M) and
PKA(5–24) (106 M), an AT2 receptor (AT2R) antagonist and a
specific PKA inhibitor, respectively, abrogated this inhibition, indi-
cating that AT2R and PKA are central in this pathway. Despite the
lack of effect of ANG-(3–4) when assayed alone in WKY rats, the
peptide (108 M) completely blocked stimulation of Na-ATPase
induced by 1010 M ANG II in normotensive rats through a mecha-
nism that also involves AT2R and PKA. Tubular membranes from
WKY rats had higher levels of AT2R/AT1R heterodimers, which
remain associated in 1010 M ANG II and dissociate to a very low
dimerization state upon addition of 108 M ANG-(3–4). This lower
level of heterodimers was that found in SHR, and heterodimers did not
dissociate when the same concentration of ANG-(3–4) was present.
Oral administration of ANG-(3–4) (50 mg/kg body mass) increased
urinary Na concentration and urinary Na excretion with a simul-
taneous decrease in systolic arterial pressure in SHR, but not in WKY
rats. Thus the influence of ANG-(3–4) on Na transport and its
hypotensive action depend on receptor association and on blood
pressure.
ANG-(3–4); kidney proximal tubules; ouabain-resistant Na-ATPase;
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SPONTANEOUSLY HYPERTENSIVE rats (SHR) are a suitable model
for the study of mechanisms underlying the genesis of essential
hypertension. Despite the vast number of studies since the
development of this animal line (27), several important issues
remain poorly understood, including those linked to the role of
the renin-angiotensin-system (RAS) and small ANG II-derived
peptides, such as ANG-(3–4), which are easily formed with the
aid of a broad ensemble of peptidases (13) in body fluids (2)
and kidneys (35). The kidneys, which are key organs for the
onset and establishment of hypertension in SHR (11), have the
ability to concentrate ANG-(3–4) (23), thereby making them a
potential target for antihypertensive effects of the dipeptide, a
general feature of all ANG II-derived small peptides.
The antihypertensive actions of ANG-(3–4), described over
a decade ago (34), were primarily attributed to inhibition of the
ANG I-converting enzyme (ACE) (15, 19). We have since
demonstrated that ANG-(3–4) powerfully antagonizes the ef-
fects of ANG II upon the Ca2-ATPase resident in basolateral
membranes of proximal tubule cells (4, 6). This pump is
probably responsible for the fine control of cytosolic Ca2
in proximal tubule cells (8) and consequently of fluid
reabsorption across the proximal tubular epithelium, which
is modulated by cytosolic Ca2 fluctuations (9, 12). Thus we
hypothesized that ANG-(3– 4) could also interact with Na-
transporting mechanisms, especially those mediated by
Na-transporting ATPases.
Two ATPases are involved in the active reabsorption of Na
in proximal tubule cells: the classic Na-K-ATPase (14) and
the ouabain-resistant Na-ATPase (28). The latter, recently
cloned and purified from epithelial cells (31, 32), is an impor-
tant target for a possible modulatory effect of ANG-(3–4)
because 1) it is considered to be the key pump for fine-tuning
of Na reabsorption in the renal proximal tubule (7); and 2) it
is upregulated in SHR (29), where blood pressure values are
sensitive to ANG-(3–4) (34).
Our main hypothesis is that the Na-ATPase resident in
proximal tubule cells of SHR could be responsive to ANG-
(3–4) concentrations in the range reported in renal tissue (24).
We also postulate that type 2 ANG II receptors (AT2R)
associated with the antihypertensive actions of ANG II (29, 36)
could be central to the mechanism of the responses of Na-
ATPase to ANG-(3–4).
MATERIALS AND METHODS
Animals. Eleven-week-old SHR (obtained from CEDEME/
UNIFESP) and age-matched WKY rats (obtained from CEMIB/
UNICAMP) were used. This age was selected because ANG-(3–4)
has its maximum blood pressure-lowering effect in SHR at this age
(34). All procedures were approved by the Committee for Experimen-
tal and Animal Ethics at the Federal University of Rio de Janeiro
(protocol IBCCF106) and performed in accordance with its recom-
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mendations. The animals were kept for at least 72 h in a room at 22
3°C with a 12:12-h light-dark cycle with access to a standard rat chow
and water ad libitum.
Determination of arterial pressure and in vivo Na excretion.
After adaptation of the animals for 24 h in metabolic cages and, after
an additional 24 h, urine samples were collected to measure Na
concentration and volume. A single oral dose of 50 mg/kg ANG-(3–4)
(EZBiolab, Carmel, IN) was given by gavage 3 h later. After a further
24 h, urine samples were collected again to measure the effect of
ANG-(3–4) on Na excretion. Urinary Na was measured by the
uranyl magnesium acetate precipitation method with a commercial kit
(sodium rapid, Human, Wiesbaden, Germany).
The arterial pressure of the animals was measured by the nonin-
vasive tail-cuff method (Letica 5002 storage pressure meter, Letica
Scientific Instruments, Barcelona, Spain). Three independent mea-
surements were taken after 10 min at 30–32°C. The rats were
checked to ensure that they stopped moving before arterial pressures
were read. After a 3-h recovery period, a single oral dose of 50 mg/kg
ANG-(3–4) was given by gavage. Arterial pressure was monitored as
described above at 3, 6, and 24 h after ANG-(3–4) administration.
Isolation of proximal tubule cell membranes. Proximal tubule cell
membranes were isolated as previously described (40) from slices of
the outer part of the kidney cortex (cortex corticis), where 90% of
the cell population correspond to proximal tubules (41). The final
membrane fraction was suspended in 250 mM sucrose (pH 7.4), and
aliquots were stored in liquid N2. Total protein concentration was
determined by the Folin method (18).
Measurement of Na-ATPase and Na-K-ATPase activity. The
activity of the two Na pumps was measured by quantification of Pi
released during ATP hydrolysis, using a colorimetric method (38).
Ouabain-resistant Na-ATPase activity was determined by the differ-
ence between ATP hydrolysis in the absence and presence of its
inhibitor, furosemide (both measurements were made in the presence
of 1 mM ouabain). For quantification of Na-ATPase activity, the
reaction was started by adding the membrane preparation (final
concentration 0.1 mg/ml), previously incubated for 10 min at 37°C
with 1 mM ouabain to guarantee Na-K-ATPase inhibition, to the
reaction media containing 20 mM HEPES-Tris (pH 7.0), 10 mM
MgCl2, 120 mM NaCl, 5 mM ATP, and the specific inhibitors or
peptides tested in each experimental set.
Na-K-ATPase activity was determined by the difference be-
tween ATP hydrolysis in the absence and presence of its specific
inhibitor, ouabain. For quantification of Na-K-ATPase activity, the
membrane preparation (final concentration 0.05 mg/ml) was added to
the reaction mixture containing 50 mM Bis-Tris-propane (pH 7.4), 0.2
mM EDTA, 5 mM MgCl2, and 120 mM NaCl. After incubation for 10
min at 37°C, the reaction was started by adding a mix of ATP (5 mM)
and KCl (24 mM).
Fig. 1. ANG-(3–4) inhibits the ouabain-insensitive Na-ATPase in spontaneously hypertensive rats (SHR) but not in Wistar-Kyoto (WKY) rats. Values are
means SE of 4–9 determinations in triplicate from different membrane preparations. A: concentration dependence of the inhibition by ANG-(3–4) on proximal
tubule Na-ATPase from SHR in the range shown on the abscissa. Different lower-case letters above the symbols indicate statistical differences among the
corresponding mean values [“a” symbols correspond to P values ranging from 0.427 to 0.638 with respect to the assay in the absence of ANG-(3–4); “b” symbols
correspond to P 0.005 and P 0.001 for the conditions 108 and 106 M ANG-(3–4) compared with the control given no peptide]. Differences were assessed
by 1-way ANOVA followed by a Newman-Keuls posttest. B: Na-ATPase from WKY rats is insensitive to ANG-(3–4). A horizontal line (82.1  3.1 nmol
Pi·mg1·min1; mean  SE) is adjusted to the experimental points. No statistical differences were found among mean values (P  0.240 for 1-way ANOVA;
posttest was not carried out). C and D: proximal tubule Na-K-ATPase is insensitive to ANG-(3–4) in both SHR and WKY rats. Horizontal lines are adjusted
to the experimental points (183.7  6.1 nmol Pi·mg1·min1 for SHR; 193.3  6.1 nmol Pi·mg1·min1 for WKY rats). No statistical differences were found
between the mean values of activities at different ANG-(3–4) concentrations with each strain (P  0.843 for SHR and P  0.730 for WKY rats; posttest was
not carried out).
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Detection of AT1/AT2 receptor heterodimers (AT1R/AT2R) by im-
munoprecipitation followed by Western blot analysis. Membranes (0.5
mg/ml) were initially incubated in sucrose (pH 7.4) for 20 min at 37°C
with 1010 M ANG II (Sigma-Aldrich, St. Louis, MO) or 108 M
ANG-(3–4) and solubilized for 30 min at room temperature with
0.01% CHAPS (wt/vol). This mixture was diluted in RIPA buffer [50
mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% NP-40 (vol/vol), 0.25%
sodium deoxycholate, and 1 mM EDTA], in a final volume of 1 ml
and incubated with the monoclonal anti-AT1R antibody (TONI-1,
1:100, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at 4°C.
Subsequently, protein A/G-agarose (1:50, Santa Cruz Biotechnology)
was added and left overnight at 4°C under gentle agitation. The
immunoprecipitates were separated from supernatants by centrifuga-
tion at 1,000 g for 5 min (4°C) and washed three times with
Tris-buffered saline. The resulting pellets were mixed with Laemmli
buffer, heated for 4 min at 100°C, and centrifuged to remove protein
A/G-agarose. Aliquots of the receptor-containing supernatants were
electrophoresed on 10% SDS-PAGE, transferred to nitrocellulose
membranes, and probed with anti-AT2R (C-18, Santa Cruz Biotech-
nology) antibody (1:500) to detect receptor heterodimers. Membranes
were stripped for 30 min at 55°C with 0.2 M glycine (pH 2.2) and
reprobed with anti-AT1R antibody (N-10, 1:500, Santa Cruz Biotech-
nology). The intensity of the bands at 45 kDa was measured by
image-analysis software (Scion Image 4.0.3.2), and the amount of
AT1R/AT2R heterodimers was determined by the ratio of AT2R to
AT1R band intensities.
Fig. 2. Oral administration of ANG-(3–4) (50
mg/kg body wt) decreases systolic arterial pres-
sure and increases urinary Na excretion in SHR
(left) but not in WKY rats (right). Different low-
er-case letters above the symbols indicate statis-
tical differences among the corresponding mean
values. Systolic arterial pressure was monitored 3
h before (Pre) and 3, 6, and 24 h after ANG-(3–4)
treatment to SHR (A) and WKY rats (E; n  10
in all times; each value corresponds to 3 succes-
sive measurements in a period of 10–15 min). In
A, P  0.001 (3 h vs. Pre), P  0.001 (6 h vs.
Pre), P  0.100 (24 h vs. Pre). Differences were
assessed by 1-way ANOVA followed by a New-
man-Keuls posttest. In E, P  0.060 (1-way
ANOVA without posttest). For urinary Na anal-
ysis, 24 h-urine samples were collected before
(Pre) and after (Post) a single oral dose of ANG-
(3–4). B and F: urinary volume (UV) corrected
by the body weight in SHR (n  10, before and
after; P  0.489) and WKY rats (n  10; P 
0.562). C and G: urinary Na concentration
([Na]ur) in SHR (n  10; P  0.033) and WKY
rats (n  10; P  0.972). D and H: urinary Na
excretion in 24 h (UNaV) in SHR (n  10; P 
0.001) and WKY rats (n  10; P  0.523).
Differences were assessed by unpaired t-test
within each strain.
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Statistical analysis. Data were plotted and analyzed using GraphPad
Prism 5.01. The results are expressed as means  SE. Student’s t-test
was used for comparison between two means, whereas three or more
means were compared by one-way ANOVA, followed by a Newman-
Keuls multiple comparison test. Values were considered significantly
different at P  0.05. Sigma Plot 12.5 software was used to calculate
exact P values in multiple comparisons.
RESULTS
Inhibition of renal ouabain-resistant Na-ATPase by ANG-
(3–4) in SHR. ANG-(3–4) selectively inhibits in a dose-
dependent manner Na-ATPase activity resident in the plasma
membranes from kidney proximal tubules cells of SHR rats
(Fig. 1A) without influencing the WKY rats (Fig. 1B), indicat-
ing that the dipeptide actions on Na transport are conditioned
by alterations that contribute to the onset of hypertension.
Selectivity is also seen in the molecular machinery involved in
proximal Na reabsorption. The Na-K-ATPase does not
seem to be a target for ANG-(3–4), at least in isolated mem-
branes from either SHR (Fig. 1C) or WKY rats (Fig. 1D).
A single oral dose of ANG-(3–4) stimulates Na excretion
in SHR. To test whether ANG-(3–4) has an effect on Na-
ATPase associated with modifications in Na excretion by
SHR, despite the absence of influence on Na-K-ATPase
activity, the dipeptide was administered in a single oral dose of
50 mg/kg body wt. Three hours after ANG-(3–4) administra-
tion, SHR exhibited lower systolic arterial pressure (Fig. 2A),
an antihypertensive effect that still persisted 6 h after ANG-
(3–4). The pressure levels returned to the initial elevated
values 1 day after administration. The dipeptide also increased
the 24-h Na excretion in SHR (UNaV) due to increased
urinary Na concentration ([Na]ur) without significantly aug-
menting urinary flow (UV) (Fig. 2, B–D). As in the case of
Na-ATPase activity, none of these parameters were modified
after ANG-(3–4) treatment in WKY rats (Fig. 2, E–H).
AT2R and PKA are components of a signaling pathway
involved in inhibition of Na-ATPase by ANG-(3–4) in SHR.
We previously showed that AT2R is the first step in a signaling
cascade that ultimately has the basolateral plasma membrane
Ca2-ATPase from kidney proximal cells as a target for
femtomolar ANG-(3–4) concentrations (4, 6). To establish
whether this class of receptors participates in the same pathway
that culminates in the inhibition of Na-ATPase in SHR, the
influence of the AT2R antagonist PD123319 was examined.
PD123319 (107 M) completely suppressed the inhibitory
effect of 108 M ANG-(3–4), which is indicative of this
participation (Fig. 3A). Conversely, involvement of AT1R is
unlikely because 107 M losartan had no effect upon the
inhibition caused by ANG-(3–4) (Fig. 3B). Looking down-
stream for a key effector of a signal generated at the AT2R
level, full reversal of the inhibition due to 106 M PKA(5–24)
peptide, the specific inhibitor of PKA, points to its involvement
in the inhibition of Na-ATPase from SHR (Fig. 3C).
Stimulatory action of ANG II on Na-ATPase in WKY, but
not the inhibitory one in SHR, are modified by ANG-(3–4).
ANG II is a physiological modulator of Na-ATPase in WKY
rats via AT1R ¡ PKC (30), ANG II depresses the activity of
the pump in SHR rats via AT2R (29), and ANG-(3–4) inhibits
Na-ATPase activity in SHR via AT2R¡ PKA (Figs. 1A and
3, A, and C). Therefore, we assayed the two peptides in the
combinations shown in Fig. 4 to investigate their possible
Fig. 3. AT2 receptor (AT2R) and PKA participate in the signaling cascade that
culminates in the inhibition of Na-ATPase by ANG-(3–4). Na-ATPase
activity was assayed in the absence or presence of ANG-(3–4) in combination
with PD123319 (A), PKA(5–24) peptide (B), or losartan (C), as shown on the
respective abscissa. Values are means SE of 4–8 determinations in triplicate
using different membrane preparations. Different lower-case letters above the
bars indicate statistical difference among mean values. In A, P  0.003 for
ANG-(3–4) vs. control without additions, P  0.767 for ANG-(3–4) plus
PD123319 vs. control, and P  0.785 for PD123319 alone vs. control. In B,
P 0.002 for ANG-(3–4) vs. control, P 0.010 for ANG-(3–4) plus losartan
vs. control, and P  0.479 for losartan vs. control. In C, P  0.010 for
ANG-(3–4) vs. control without additions, P  0.380 for ANG-(3–4) plus
PKA(5–24) vs. control and P  0.632 for PKA(5–24) vs. control.
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interactions at the level of Na-ATPase from normotensive
and hypertensive rats. The results show that only the stimulus
of 1010 M ANG II on Na-ATPase in WKY rats, possibly a
prohypertensive action, is cancelled by 108 M ANG-(3–4)
(Fig. 4A). Inhibition of the pump by 1010 M ANG II in SHR
was not modified by the dipeptide (108 M), which gave
similar inhibition alone (Fig. 4B).
AT2R and PKA participate in the counteracting action of
ANG-(3–4) upon stimulation of Na-ATPase by ANG II. We
investigated whether the same signaling route involved in the
inhibition of Na-ATPase in SHR participates in the counter-
acting effect of ANG-(3–4) on the activation of Na-ATPase
by ANG II in WKY rats. This hypothesis was confirmed, as
shown by the results in Fig. 5. When 107 M PD123319 was
added together with ANG-(3–4), the full stimulatory effect of
ANG II is preserved (Fig. 5A), strong evidence of the partici-
pation of AT2R. When the inhibitor PKA(5–24) (106 M) was
present alone (Fig. 5B), Na-ATPase activity reached the
levels found with ANG II, confirming that PKA activity plays
a key downstream role in the mechanism involved in the
regulation of the pump by ANG II/ANG-(3–4).
ANG-(3–4) does not induce dissociation of AT1R/AT2R
dimers in proximal tubule membranes in SHR, a physiological
outcome encountered in WKY rats. We had earlier postulated
that dissociation of AT1R/AT2R dimers is an important feature
in the signaling mechanism associated with the recovery by
ANG-(3–4) in basolateral plasma membrane Ca2-ATPase
activity that is inhibited by picomolar ANG II concentrations
(4, 6). ANG-(3–4) at 108 M dissociated 50% of the AT1R/
AT2R dimers detected in the proximal tubule membranes of
WKY rats, whereas 1010 M ANG II had no effect (Fig. 6).
The SHR present an AT1R/AT2R dimer population that is 1)
Fig. 4. ANG-(3–4) suppresses the stimulation by ANG II of Na-ATPase activity in WKY rats, whereas it does not modify the inhibition seen in SHR. ANG
II and ANG-(3–4) were assayed in the combinations shown on the abscissa. Values are means SE of 4–5 determinations in triplicate using different membrane
preparations. A: WKY rats. B: SHR. Different lower-case letters above the bars indicate statistical differences among mean values. In A, P  0.009 for 1010
M ANG II vs. control with no peptides, P  0.491 for 1010 ANG II plus ANG-(3–4) vs. control, and P  0.301 for 108 M ANG-(3–4) vs. control. In B,
values with “b” correspond to P  0.008 for 1010 M ANG II vs. control with no peptides, P  0.001 for 1010 M ANG II plus 108 M ANG-(3–4) vs. control,
and P  0.001 for 108 M ANG-(3–4) vs. control.
Fig. 5. AT2R and PKA participate in the signaling cascade associated with the counteracting effect of ANG-(3–4) upon the stimulus of Na-ATPase by ANG
II in normotensive rats. Values are means SE of 4–5 determinations in triplicate using different membrane preparations. Assays were carried out in the presence
of ANG II and ANG-(3–4) with PD123319 (A) or PKA(5–24) peptide (B). Different lower-case letters above the bars indicate statistical differences among mean
values. In A, P  0.047 for 1010 M ANG II vs. control without additions, P  0.032 for 1010 M ANG II together with 108 M ANG-(3–4) plus 107 M
PD123319 vs. control, P  0.302 for 1010 M ANG II plus 108 M ANG-(3–4) vs. control, and P  0.506 for PD123319 alone vs. control. In B, P  0.013
for 1010 M ANG II vs. control without additions, P 0.245 for 1010 M ANG II plus 108 M ANG-(3–4) vs. control, P 0.047 for 1010 M ANG II together
with ANG-(3–4) plus 106 M PKA(5–24), and P  0.032 for PKA(5–24) alone vs. control.
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smaller than in WKY, 2) similar to that in WKY rats after the
ANG-(3–4)-induced dissociation, and 3) completely insensi-
tive to ANG-(3–4).
DISCUSSION
Besides the classic view of the RAS being restricted to ANG
I and ANG II, experimental evidence over the last three
decades indicates the existence of a great constellation of small
ANG II-derived peptides in the kidney (35) and in other organs
(13), but their physiological role remains relatively obscure.
Among these peptides, the smaller is ANG-(3–4), whose
antihypertensive properties were first described by Saito et al.
(34), has received little attention despite its well-documented
action on the cardiovascular system as a whole (19, 15, 24, 37).
The circulating levels of this dipeptide are up to three times
lower in hypertensive human subjects compared with normo-
tensive controls, and their plasma levels correlate inversely
with systolic arterial pressure (20), indicating that endoge-
nously formed ANG-(3–4) is important in regulating arterial
blood pressure. This dipeptide also has vasodilating (37, 39),
antiproliferative (24), and antioxidant (39) effects.
Interactions between ANG-(3–4) and RAS seem to occur
beyond those at the ANG II receptor level. Matsui et al. (25)
demonstrated that ANG-(3–4) and captopril compete for the
same absorption site in the jejunal membranes, with a subse-
quent decrease in the plasma levels of the antihypertensive
drug and that combined oral administration of both compounds
to SHR attenuates their respective blood pressure-lowering
effect. These observations could mean that ANG-(3–4) inter-
acts with ANG II, forming enzymatic pathways by binding at
the catalytic site of the ACE (15, 19).
We have now demonstrated a specific dose-dependent in-
hibitory influence of ANG-(3–4) on Na-ATPase activity in
the proximal tubule cells of SHR, but not in WKY rats.
Inhibition occurs only in hypertensive rats that have hyperac-
tive AT1R-linked signaling pathways in their proximal tubules
and a constitutively high Na-ATPase activity (29), which
raised the hypothesis that ANG-(3–4) acts through the AT2R
receptors. The signaling pathways associated with this class of
receptors can elicit counteracting responses to those originating
in AT1R (26), although they can act through specific mecha-
nisms and pathways unrelated to those of AT1R (33). Since the
AT2R antagonist PD123319 or the PKA inhibitor PKA(5–24)
completely cancelled the effect of ANG-(3–4) constitutes
strong evidence for a signaling network that, starting with
AT2R being bound by the peptide, activates a cAMP-mediated
downstream pathway that culminates in the downregulation of
Na-ATPase in the basolateral membranes of SHR. Thus the
Na flux mediated by this pump is depressed and can be seen
as an antihypertensive action at renal level.
This view is supported by fact that the in vitro inhibitory
effect of ANG-(3–4) on Na-ATPase matches those obtained
in vivo regarding the influence of the peptide increasing the
total Na excretion in 24 h and transiently lowering systolic
blood pressure. Taking these data as a whole demonstrates that
changes in Na-ATPase in hypertensive rats, without changes
in Na-K-ATPase, result in parallel changes in overall renal
Na transport and, consequently, in a global antihypertensive
action. The selective influence on Na-ATPase can explain the
lack of effect on urinary flux with a simultaneous rise in
urinary Na concentration and total Na excretion over 24 h
after a single dose of ANG-(3–4). Since this pump is consid-
ered the fine tuner of proximal Na reabsorption, whereas the
Na-K-ATPase is responsible for the bulk reabsorption (7),
the natriuretic effect of ANG-(3–4) seems to arise from a
delicate and specific impact of great physiological significance
upon only one Na pump, without affecting water balance.
The selective influence on renal Na-ATPase of SHR, as
well as the earlier observations that ANG-(3–4) decreases
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Fig. 6. ANG-(3–4) induces dissociation of AT1R/AT2R dimers in WKY rats
but not in SHR. Proximal tubule cell membranes from WKY rats and SHR
were incubated with ANG II and ANG-(3–4), in the combinations shown on
the abscissa, before receptor immunoprecipitation (lanes 1–3, 5–7). A: repre-
sentative immunodetection of AT2R using a goat polyclonal antibody after
immunoprecipitation using a mouse monoclonal antibody against AT1R. B: re-
presentative immunodetection of AT1R in the same nitrocellulose membrane
using a rabbit polyclonal antibody. C: densitometric quantification of AT2R
and AT1R immunosignals from 5 experiments using different membrane
preparations. Bars represent AT2R-to-AT1R density ratios. Different lower-
case letters above the bars indicate statistical differences between mean values.
For WKY rats, P 0.799 for 1010 M ANG II vs. control with no peptides and
P  0.037 for 108 M ANG-(3–4) vs. control. For SHR, P  0.969 for 1010
M ANG II vs. control with no peptides and P 0.950 for 108 M ANG-(3–4)
vs. control. Comparison between WKY rats and SHR with no peptides (first
columns in each panel): P  0.031. The negative control is shown in lane 4 (A
and B). Immunoprecipitation was carried out in WKY membranes in the
absence of the AT1R monoclonal antibody.
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arterial blood pressure in hypertensive (15), but not in normo-
tensive humans (21), gives experimental support to the idea
presented above that ANG-(3–4) acts on proximal Na trans-
port under conditions that culminate in well-established hyper-
tension. However, the physiological role of ANG-(3–4) is
clearly not restricted to hypertensive animals. ANG II is a key
physiological activator of renal Na-ATPase (7, 30). Since
108 M ANG-(3–4) blocks stimulation of Na-ATPase in
WKY rats due to 1010 M ANG II, it is now clear that
interacting regulatory actions between the two peptides seems
to have important physiological significance. This adds support
to the view that the effect of ANG-(3–4) is only significant
when Na-ATPase is activated, in either physiological or
pathological conditions. This rationale has additional support;
ANG-(3–4) is ineffective in modulating the inhibitory effect of
1010 M ANG II on the constitutively hyperactive Na-
ATPase of SHR. AT2R and the regulatory phosphorylation
mediated by PKA also seems to play a role in the counteracting
effect of ANG-(3–4) in normotensive rats. In the presence of
ANG-(3–4), PD123319 (107 M), or PKA(5–24) (106 M)
returned Na-ATPase activity to the stimulated values ob-
tained with ANG II alone.
The activity of Ca2 ions plays a key role in the regulation
of transport of fluid across the proximal tubular epithelium in
a pathway involving PKC (9, 10). The ANG-(3–4)¡ AT2R¡
PKA cascade is an extremely potent reactivator in the femto-
molar range (6) of basolateral plasma membrane Ca2-ATPase
inhibited by 1010 M ANG II (4), which occurs via a PKC-
mediated pathway (3). Previous observations seen in the con-
text of those described herein lead us to postulate a regulatory
network in proximal tubule cells that involves antagonistic and
interacting effects of ANG II/ANG-(3–4), and AT1R/AT2R
and PKC/PKA as being involved in the regulation of Na
reabsorption and, ultimately, in the physiological regulation of
blood pressure. However, these signaling molecules and effec-
tors certainly are involved with other player mechanisms not
covered in this report. In phosphoproteomic analysis of ANG
II-mediated responses in proximal tubule cells, several PKC
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Fig. 7. Proposed model for the Na-ATPase
modulation by ANG II and ANG-(3–4) in
WKY rats (A) and SHR (B). In normotensive
WKY animals, the basal activity of Na-
ATPase (central transmembrane cylinder) is
determined by the balance between activat-
ing phosphorylation mediated by PKC (30)
and inhibitory phosphorylation mediated by
PKA (Fig. 5B). ANG II activates PKC after
interaction with AT1R/AT2R heterodimers,
as previously demonstrated for renal Ca2-
ATPase (3, 4). ANG-(3–4) promotes disso-
ciation of the heterodimers (Fig. 6), binds to
AT2R (Fig. 5A), and favors PKA activation
(Fig. 5B), thus blocking the activation of the
pump by ANG II (Fig. 4A). In SHR, a higher
basal PKC activity (16) leads to an imbalance
between regulatory phosphorylations, and
consequently to hyperactivation of the Na
pump. The hypertensive animals have a
smaller number of heterodimers (Fig. 6), thus
favoring the interactions of ANG II with
monomeric AT2R, leading to activation of
PKA and inhibition of the Na pump, the
same and nonadditive effect observed with
ANG-(3–4) (Fig. 4B). Small circles, amino
acids in ANG II and ANG-(3–4) sequences;
large circles in the intracellular aspect of the
Na-ATPase molecule, stimulatory phos-
phorylations of Na-ATPase mediated by
PKC; squares, inhibitory phosphorylations
mediated by PKA. Large vertical arrows in-
dicate conversion of ANG II to ANG-(3–4)
in basolateral membranes of proximal tubule
cells (4); thin black arrows from the kinases
indicate stimulus of the corresponding acti-
vating (PKC) or inhibitory (PKA) phospho-
rylations of Na-ATPase; truncated arrows
indicate blockade of PKC-mediated activa-
tion of the pump upon activation of PKA.
Horizontal double-headed black arrow in
WKY represents AT1R/AT2R dissociation
induced by ANG-(3–4).
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isoforms, cAMP-responsive proteins, and MAPK and ERK1/2
become phosphorylated, depending on whether pressor or
nonpressor doses of ANG II are used (17). The constitutive
ratio of PKC/PKA activity in proximal tubules could also play
an important role in the physiological action of ANG-(3–4) in
modulating Na-ATPase in normotensive and hypertensive
rats. This ratio is higher in SHR than in WKY rats (16); for this
reason, only the latter animals respond to PKA(5–24) alone by
augmentation of Na-ATPase levels to those found with ANG
II alone. When the AT1R¡ PKC pathway is overactive, as in
SHR, the effect of PKA(5–24) alone is no longer apparent.
The formation of AT2R/AT1R heterodimers and its potential
physiological relevance were reported over a decade ago (1),
the association being considered proof of the antagonistic
effects of AT2R on the AT1R functions. However, mutual
signaling between the two classes of receptors seems to be
more complex in the membranes of proximal tubule cells. The
supramolecular organization of AT1R and AT2R in proximal
tubule cell membranes as well as the relative amounts of
monomers are important features in both the constitutive status
of the tensional levels in SHR and WKY rats and in the
responses to ANG-(3–4) and ANG II.
SHR membranes have fewer AT1R/AT2R heterodimers
compared with normotensive WKY rats, which might be re-
lated to the absolute expression of AT1R and AT2R. In a
similar cell membrane fraction of the proximal tubules, this
AT2R expression is significantly lower in SHR compared with
WKY (16). This could explain the higher proportional amount
of heterodimers in WKY; since these animals have more
AT2R, a higher proportion of total AT1R should be found in the
dimeric state. In SHR, the lower AT2R content leaves a greater
amount of total AT1R immunoprecipitated in the monomeric
state.
We previously demonstrated that micromolar ANG II con-
centrations, a condition in which substantial amounts of ANG-
(3–4) are formed, promote dissociation of AT2R/AT1R het-
erodimers (4). These heterodimers are required for the inhibi-
tion of the plasma membrane Ca2-ATPase by nanomolar
ANG II (3). We have now directly shown that 108 M
ANG-(3–4) reduces heterodimerization in tubule membranes
of WKY rats to the levels constitutively found in SHR. This
allows us to postulate that 1) higher levels of AT2R/AT1R are
required for the physiological stimulation of Na-ATPase in
normotensive rats, and 2) lower levels of AT2R/AT1R het-
erodimers are a prerequisite for the action of ANG-(3–4) on
Na-ATPase. The peptide could also, and at the same time,
control the equilibrium between monomeric and dimeric states
of both classes of ANG II receptors.
Finally, the possible physiological relevance of ANG-(3–4)
in the regulation of renal functions, especially of those related
to Na transport, has been highlighted by its peculiar metab-
olism and turnover. ANG-(3–4) is formed in the basolateral
membranes from ANG II, ANG III, and ANG-(1–7) from
limited proteolysis mediated by a wide ensemble of peptidases
(5). Moreover, the basal concentrations of the dipeptide in
renal tissue (7 pmol/g, i.e., 108 M) (24) are those that
were effective in this study, with the kidney having the ability
to concentrate ANG-(3–4) (24). Since the systemic antihyper-
tensive actions of exogenous ANG-(3–4) remain after the
rapid return of its plasma levels to normal values (23), it is
likely that depressor mechanisms take place at a tissue level.
For its role in blood pressure regulation, the kidney is a
privileged candidate. Interestingly, physiological ANG II (de-
tected by mass spectrometry) is required in vitro to avoid
complete degradation of ANG-(3–4) to Val and Tyr (4),
further evidence of an interplay between the pathways of ANG
II and ANG-(3–4) metabolism in the kidney cortex (5). The
proposed interactions between ANG II and ANG-(3–4) in the
basolateral membranes at the level of AT1R/AT2R- and PKC/
PKA-mediated signaling cascades in WKY rats and SHR that
emerge from our data are given in Fig. 7 (for a detailed
description, see the corresponding legend).
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